{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T14:54:48Z","timestamp":1789224888590,"version":"build-2803163510"},"reference-count":49,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinics and Practice"],"abstract":"<jats:p>Background\/Objectives: Hailey\u2013Hailey disease (HHD) is an uncommon genodermatosis with autosomal dominant inheritance caused by loss-of-function mutations in the ATP2C1 gene, which lead to disruption in keratinocyte adhesion and intraepidermal acantholysis. The chronic nature of the disease, its frequent recurrences and the lack of specific treatment pose real challenges in the long-term management of these patients. Recent studies have evaluated the effect of dupilumab, a human monoclonal antibody that blocks interleukin-4 and -13 receptor in refractory HHD, with very promising results. The aim of this study was to review the published data on the use of dupilumab for the treatment of HHD, to present our own experience in the field, and to discuss the mechanisms underlying dupilumab\u2019s beneficial effects in HHD and the future treatment perspectives. Methods: A search of the medical literature on the use of dupilumab in the treatment of HHD was conducted. The terms \u201cHailey\u2013Hailey disease\u201d, \u201cbenign familial pemphigus\u201d, \u201cbenign chronic pemphigus\u201d, and \u201cdupilumab\u201d were searched across multiple databases (Medline, Chrocane Library, EMBASE) from inception until 30 September 2024. Results: To date, six manuscripts describing 11 refractory HHD cases treated with dupilumab have been published. All the patients experienced significant clinical improvement. The authors reported sustained disease quiescence in seven patients (64%), monitored for 5 to 24 months. None of the patients experienced adverse effects related to dupilumab. To the existing evidence, we add a new case of recalcitrant HHD successfully treated with dupilumab. Conclusions: Mounting evidence indicates dupilumab as a safe and efficient therapeutic alternative in patients with severe, refractory HHD. However, the long-term efficacy of dupilumab and the optimal therapeutic regimen for HHD are yet to be determined.<\/jats:p>","DOI":"10.3390\/clinpract15030048","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T06:15:33Z","timestamp":1740550533000},"page":"48","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dupilumab, a Potential Novel Treatment for Hailey\u2013Hailey Disease"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1702-7280","authenticated-orcid":false,"given":"Liliana Gabriela","family":"Popa","sequence":"first","affiliation":[{"name":"Dermatology Department, Elias Emergency University Hospital, 17 Marasti Bd., District 1, 011461 Bucharest, Romania"},{"name":"Dermatology Department, Carol Davila University of Medicine and Pharmacy, 37 Dionisie Lupu Street, District 1, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calin","family":"Giurcaneanu","sequence":"additional","affiliation":[{"name":"Dermatology Department, Elias Emergency University Hospital, 17 Marasti Bd., District 1, 011461 Bucharest, Romania"},{"name":"Dermatology Department, Carol Davila University of Medicine and Pharmacy, 37 Dionisie Lupu Street, District 1, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentina","family":"Zaharia","sequence":"additional","affiliation":[{"name":"Dermatology Department, CF 2 Clinical Hospital, 63 Marasti Bd., District 1, 011464 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreea","family":"Grigoras","sequence":"additional","affiliation":[{"name":"Dermatology Department, Elias Emergency University Hospital, 17 Marasti Bd., District 1, 011461 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2038-6030","authenticated-orcid":false,"given":"Alexandra Denisa","family":"Oprea","sequence":"additional","affiliation":[{"name":"Dermatology Department, Elias Emergency University Hospital, 17 Marasti Bd., District 1, 011461 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-576X","authenticated-orcid":false,"given":"Cristina","family":"Beiu","sequence":"additional","affiliation":[{"name":"Dermatology Department, Elias Emergency University Hospital, 17 Marasti Bd., District 1, 011461 Bucharest, Romania"},{"name":"Dermatology Department, Carol Davila University of Medicine and Pharmacy, 37 Dionisie Lupu Street, District 1, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"ref_1","unstructured":"Bolognia, J., Jorizzo, J., and Schaffer, J. (2012). Darier disease and Hailey\u2013Hailey disease. Dermatology, Elsevier Inc.. [3rd ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jdcr.2024.07.008","article-title":"Hailey\u2013Hailey disease successfully treated with tralokinumab and literature review of successful treatment with dupilumab","volume":"52","author":"Garg","year":"2024","journal-title":"JAAD Case Rep."},{"key":"ref_3","unstructured":"Konstantinou, M.P., and Krasagakis, K. (2024, September 15). Benign Familial Pemphigus (Hailey\u2013Hailey Disease); StatPearls Publishing, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK585136\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.abd.2023.12.003","article-title":"Hailey\u2013Hailey disease: Clinical, diagnostic and therapeutic update","volume":"99","author":"Porro","year":"2024","journal-title":"Anais Bras. Dermatol."},{"key":"ref_5","unstructured":"Hailey\u2013Hailey Disease (2024, September 15). NORD (National Organization for Rare Disorders). Available online: https:\/\/rarediseases.org\/rare-diseases\/hailey-hailey-disease\/."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1001\/jamadermatol.2013.6880","article-title":"What\u2019s in a name?: Hailey\u2013Hailey disease","volume":"149","author":"Orseth","year":"2013","journal-title":"JAMA Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40257-019-00477-z","article-title":"Hailey\u2013Hailey Disease: An Update Review with a Focus on Treatment Data","volume":"21","author":"Ashack","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_8","unstructured":"Kang, S., Amagai, M., Bruckner, A.L., Enk, A.H., Margolis, D.J., McMichael, A.J., and Orringer, J.S. (2018). Acantholytic disorders of the skin. Fitzpatrick\u2019s Dermatology in General Medicine, Mcgraw-Hill Education. [9th ed.]."},{"key":"ref_9","first-page":"201","article-title":"Generalized Hailey\u2013Hailey disease triggered by nonsteroidal antiinflammatory drug-induced rash: Case report","volume":"20","author":"Chlebicka","year":"2012","journal-title":"Acta Dermatovenerol. Croat."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1468-3083.2008.02979.x","article-title":"Development of familial benign chronic pemphigus in a patient undergoing treatment with efalizumab for psoriasis","volume":"23","author":"Saavedra","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1067\/mjd.2000.100542","article-title":"Squamous cell carcinoma arising in Hailey\u2013Hailey disease","volume":"43","author":"Holst","year":"2000","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.clindermatol.2015.04.006","article-title":"Hailey\u2013Hailey disease: A fold (intertriginous) dermatosis","volume":"33","author":"Engin","year":"2015","journal-title":"Clin. Dermatol."},{"key":"ref_13","first-page":"e62701","article-title":"Treatment of Recalcitrant Hailey\u2013Hailey Disease With Naltrexone and Dupilumab: A Report of Two Cases","volume":"16","author":"Santoso","year":"2024","journal-title":"Cureus"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jdcr.2023.10.004","article-title":"Recalcitrant Hailey\u2013Hailey disease successfully treated with topical ruxolitinib cream and dupilumab","volume":"42","author":"Khang","year":"2023","journal-title":"JAAD Case Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ad.2022.05.042","article-title":"Successful Treatment of Hailey\u2013Hailey Disease With Dupilumab","volume":"114","author":"Pestana","year":"2023","journal-title":"Actas Dermo-Sifiliogr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/ijd.16322","article-title":"A case of Hailey\u2013Hailey disease successfully treated with dupilumab","volume":"61","author":"Licata","year":"2022","journal-title":"Int. J. Dermatol."},{"key":"ref_17","first-page":"e776","article-title":"Dupilumab in Hailey\u2013Hailey disease: A case series","volume":"36","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/bjd.20475","article-title":"Hailey\u2013Hailey disease treated with dupilumab: A case series","volume":"185","author":"Alzahrani","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3000605241286832","DOI":"10.1177\/03000605241286832","article-title":"IL-13 inhibition in the treatment of atopic dermatitis\u2014New and emerging biologic agents","volume":"52","author":"Teixeira","year":"2024","journal-title":"J. Int. Med. Res."},{"key":"ref_21","first-page":"1254","article-title":"Hailey\u2013Hailey disease and review of management","volume":"13","author":"Chiaravalloti","year":"2014","journal-title":"J. Drugs Dermatol."},{"key":"ref_22","unstructured":"(2024, September 15). ATP2C1 ATPase Secretory Pathway Ca2+ Transporting 1 [Homo sapiens (Human)], Available online: https:\/\/www.ncbi.nlm.nih.gov\/gene\/27032."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bbrc.2015.02.004","article-title":"Ca2+ homeostasis and endoplasmic reticulum (ER) stress: An integrated view of calcium signaling","volume":"460","author":"Krebs","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"26517","DOI":"10.1074\/jbc.M703029200","article-title":"Loss of the Atp2c1 secretory pathway Ca2+-ATPase (SPCA1) in mice causes Golgi stress, apoptosis, and midgestational death in homozygous embryos and squamous cell tumors in adult heterozygotes","volume":"282","author":"Okunade","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7878","DOI":"10.1074\/jbc.RA118.006250","article-title":"An N-terminal Ca2+-binding motif regulates the secretory pathway Ca2+\/Mn2+-transport ATPase SPCA1","volume":"294","author":"Chen","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1196\/annals.1306.018","article-title":"Manganese-induced parkinsonism and Parkinson\u2019s disease","volume":"1012","author":"Olanow","year":"2004","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"eadd9742","DOI":"10.1126\/sciadv.add9742","article-title":"Cryo-EM structures of human SPCA1a reveal the mechanism of Ca2+\/Mn2+ transport into the Golgi apparatus","volume":"9","author":"Chen","year":"2023","journal-title":"Sci. Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1471-4159.2012.07888.x","article-title":"High levels of Mn2+ inhibit secretory pathway Ca2+\/Mn2+-ATPase (SPCA) activity and cause Golgi fragmentation in neurons and glia","volume":"123","author":"Wuytack","year":"2012","journal-title":"J. Neurochem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e2259","DOI":"10.1038\/cddis.2016.147","article-title":"ATP2C1 gene mutations in Hailey\u2013Hailey disease and possible roles of SPCA1 isoforms in membrane trafficking","volume":"7","author":"Micaroni","year":"2016","journal-title":"Cell Death Dis."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Cialfi, S., Le Pera, L., De Blasio, C., Mariano, G., Palermo, R., Zonfrilli, A., Uccelletti, D., Palleschi, C., Biolcati, G., and Barbieri, L. (2016). The loss of ATP2C1 impairs the DNA damage response and induces altered skin homeostasis: Consequences for epidermal biology in Hailey\u2013Hailey disease. Sci. Rep., 6.","DOI":"10.1038\/srep31567"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1046\/j.1523-1747.2003.12472.x","article-title":"Actin reorganization is abnormal and cellular ATP is decreased in Hailey\u2013Hailey keratinocytes","volume":"121","author":"Aronchik","year":"2003","journal-title":"J. Investig. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/S0047-6374(01)00242-1","article-title":"Increased calcium vulnerability of senescent cardiac mitochondria: Protective role for a mitochondrial potassium channel opener","volume":"122","author":"Jahangir","year":"2001","journal-title":"Mech. Ageing Dev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.bbamcr.2004.08.018","article-title":"The Ca2+\/Mn2+ pumps in the Golgi apparatus","volume":"1742","author":"Dode","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.jid.2020.12.026","article-title":"SMOC1 and IL-4 and IL-13 Cytokines Interfere with Ca2+ Mobilization in Primary Human Keratinocytes","volume":"141","author":"Lyubchenko","year":"2021","journal-title":"J. Investig. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00000372-199202000-00005","article-title":"A study of keratin expression in benign familial chronic pemphigus","volume":"14","author":"Bergman","year":"1992","journal-title":"Am. J. Dermatopathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1038\/sj.jid.5700785","article-title":"Involucrin expression is decreased in Hailey\u2013Hailey keratinocytes owing to increased involucrin mRNA degradation","volume":"127","author":"Aberg","year":"2007","journal-title":"J. Investig. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"24080","DOI":"10.1074\/jbc.M002508200","article-title":"Requirement of an AP-1 site in the calcium response region of the involucrin promoter","volume":"275","author":"Ng","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_38","unstructured":"Morrell, D. (2024, September 15). Hailey\u2013Hailey Disease (Familial Benign Pemphigus). Available online: https:\/\/www.uptodate.com\/contents\/hailey-hailey-disease-benign-familial-pemphigus?search=hailey%20hailey&source=search_result&selectedTitle=1%7E15&usage_type=default&display_rank=1."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1523-1747.2002.01847.x","article-title":"Human keratinocytes express functional CD14 and toll-like receptor 4","volume":"119","author":"Song","year":"2002","journal-title":"J. Investig. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/ced.13762","article-title":"Acitretin as a successful treatment for Hailey\u2013Hailey disease","volume":"44","author":"Naidoo","year":"2019","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/bjd.12582","article-title":"Successful therapy of refractory Hailey\u2013Hailey disease with oral alitretinoin","volume":"170","author":"Ruzicka","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archderm.1971.04000150032004","article-title":"Benign familial chronic pemphigus treated with dapsone","volume":"103","author":"Sire","year":"1971","journal-title":"Arch. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jamadermatol.2018.2191","article-title":"Treatment of Severe Hailey\u2013Hailey Disease With Apremilast","volume":"154","author":"Kieffer","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1111\/1346-8138.16178","article-title":"Two cases of Hailey\u2013Hailey disease effectively treated with apremilast and a review of reported cases","volume":"48","author":"Yoto","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"422","DOI":"10.4103\/0378-6323.66597","article-title":"Benign familial pemphigus (Hailey\u2013Hailey disease) responsive to low dose cyclosporine","volume":"76","author":"Nanda","year":"2010","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1468-3083.2009.03360.x","article-title":"Methotrexate for refractory Hailey\u2013Hailey disease","volume":"24","author":"Vilarinho","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_47","unstructured":"(2024, September 15). SMOC1 Gene, Available online: https:\/\/medlineplus.gov\/download\/genetics\/gene\/smoc1.pdf."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1097\/CMR.0000000000000685","article-title":"Increased serum CCL26 level is a potential biomarker for the effectiveness of anti-PD1 antibodies in patients with advanced melanoma","volume":"30","author":"Fujimura","year":"2020","journal-title":"Melanoma Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"23357","DOI":"10.1074\/jbc.M309283200","article-title":"Eotaxin-3\/CCL26 is a natural antagonist for CC chemokine receptors 1 and 5. A human chemokine with a regulatory role","volume":"279","author":"Petkovic","year":"2004","journal-title":"J. Biol. Chem."}],"container-title":["Clinics and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2039-7283\/15\/3\/48\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:42:40Z","timestamp":1760028160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2039-7283\/15\/3\/48"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["clinpract15030048"],"URL":"https:\/\/doi.org\/10.3390\/clinpract15030048","relation":{},"ISSN":["2039-7283"],"issn-type":[{"value":"2039-7283","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]}}}